Proton therapy: A better way to kill tumors
Proton therapy is considered the most advanced form of radiation therapy, but size and cost of these giant machines have limited its use to only six cancer centers nationwide.
Current proton therapy
uses cyclotrons or synchrotrons
nearly 10 ft in
diameter and weighing up
to several hundred tons.
An enormous gantry and
bending magnets focus
and direct the beams.
Now, thanks to scientists
at Lawrence Livermore
National Laboratory,
the first compact
proton-therapy machine
one that would fit in
any major cancer center
and cost a fifth as much
as current devices is
one step closer to reality.
The new machine overcomes
the size obstacle by using
dielectric wall acceleration.
Scientists have demonstrated in
principle that this lets proton particles
accelerate to an energy of at
least 200 million eV within a lightweight,
insulated structure about
6.5-ft long. The machine won’t use
bending magnets and will change
the protons’ energy and intensity
between bursts that occur many
times per second. The new device
should also vary the energy,
intensity, and “spot” size of the
proton beam.
Charged protons were first
used to treat human cancer at the
Berkeley Radiation Laboratory
more than 50 years ago. But early
machines cost more than $100
million and required 90,000 sq ft
to house. The new device could
fit in standard radiation-treatment
suites and cost less than
$20 million.
“This technology has grown
out of work to develop compact,
high-current accelerators as flash
X-ray radiography sources for
managing nuclear-weapons stockpiles,”
says George Caporaso,
lead scientist on the project.
Conventional radiation therapy
uses high-energy X-rays that deliver
energy to all the tissues they
pass through. Doctors therefore
limit doses delivered to tumors to
minimize damage to surrounding
tissue.
Unlike high-energy X-rays, proton
beams deposit almost all of
their energy on the target, with
little ending up in healthy tissue.
This lets doctors use higher, potentially
more effective doses
than is possible with gamma radiation.
The first clinical prototype
will be tested at the UC Davis Cancer
Center, which shared funding
of the project with Livermore.